Target intelligence / Profile preview

Long intergenic non-protein coding RNA 1465 (LINC01465)

Target
LINC01465
Molecular classification
Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01

Overview

Long intergenic non-protein coding RNA 1465 (LINC01465) is a member of the lincRNA subclass of long non-coding RNAs, which are defined as regulatory RNA transcripts longer than 200 nucleotides that do not overlap with coding genes[1][5]. LINC01465 is located on chromosome 12q14.1 and has been detected at high levels in specific epithelial ovarian cancer (EOC) cell lines, where it may influence cancer cell migration and survival[2][4]. Silencing LINC01465 in cancer models reduces migration and modifies drug response, suggesting a role in gene expression networks governing tumor cell behavior. While it is not a classical therapeutic target such as a receptor or enzyme, LINC01465 and related lincRNAs attract attention for their regulatory functions and as potential diagnostic or prognostic biomarkers, especially in oncology[1][2][3][5]. The precise molecular mechanisms and broader biological implications of LINC01465 remain under investigation.

Other names
LINC01465C12orf61FLJ25590Putative uncharacterized protein encoded by LINC01465
02

Mechanism of action

Not established as a direct drug target; may mediate drug response or resistance by regulating gene networks influencing cell death or migration

03

Biological functions

Gene expression regulationChromatin remodelingTranscriptional regulationPossible involvement in cell migration and drug response in cancer
04

Disease associations

Cancer (notably epithelial ovarian cancer)Possible roles in other cancers (general lincRNAs suggested in literature, but disease specificity for LINC01465 requires further research)
05

Safety considerations

None described; as an RNA, not a direct drug target, so traditional safety concerns do not apply. Therapeutic manipulation of non-coding RNAs carries general risks such as off-target effects and delivery challenges.
06

Interacting drugs

None specifically reported for direct interaction; possible role in chemoresistance noted (e.g., malformin)
07

Biomarkers

High expression of LINC01465 in some cancer cell lines has been proposed as a potential biomarker for cancer progression or drug resistance (not established or clinically validated)

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 1465 (LINC01465).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 1465 (LINC01465).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call